Influence of the Xanthine Derivate HWA 138 on Endotoxin-Related Coagulation Disturbances: Effects in Non-Sensitized vs D-Galactosamine Sensitized Rats

Summary

We have evaluated the effects of the xanthine derivate HWA 138 in rat endotoxemia in order to 1) prevent coagulation disturbances and other endotoxin-induced physiological abnormalities and 2) to reduce mortality. We performed two studies using two different models (sensitized vs non-sensitized rats) with a similar mortality but different severity of coagulation disturbances: a) LPS (15 mg/kg) alone or with HWA 138 (80 mg/kg) as a treatment modality 30 min pre LPS, b) galactosamine (500 mg/ kg) simultaneously with LPS (100 µg/kg) with or without HWA 138 (80 mg/kg) pretreatment. Experiments c) and d) employed D-galactosamine and/or LPS similar to experiments a) and b), while HWA 138 was applied simultaneously. We found significant 1) amelioration of life-threatening coagulation disturbances in non-sensitized rats, 2) prevention of liver dysfunction in sensitized rats, 3) reduction of TNF formation in both models, and 4) improvement of survival in all groups receiving HWA 138. Our data indicate protective effects of HWA 138 against clotting disturbances either directly via reduced LPS-induced formation of procoagulant activity or indirectly via reduced TNF formation.

• REFERENCES

• 1 Galanos C, Freudenberg MA, Matsuura M, Coumbos A. Hypersensitivity to endotoxin and mechanisms of host-response. Prog Clin Biol Res 1988; 272: 295-308
• 2 Galanos C, Freudenberg MA, Reutter W. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci USA 1979; 76: 5939-5943
• 3 Müller R. On the therapy of disturbances of blood fluidity. Angiology 1985; 36: 226-234
• 4 Ward A, Clissold SP. Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy. Drugs 1987; 34: 50-97
• 5 Coccia MT, Waxman K, Soliman MH, Tominaga G, Piderski L. Pentoxifylline improves survival following hemorrhagic shock. Crit Care Med 1989; 17: 36-38
• 6 Barroso-Aranda J, Schmid-Schönbein GW. Pentoxifylline pretreatment decreases the degree of neutrophil activation during endotoxin shock and improves survival. Workshop Pentoxifylline and Analogues: Effects on Leukocyte Function, Le Mas d’Artigny 1989; p 27
• 7 Harada H, Ishizaka A, Yonemaru M, Mallick AA, Hatherill JR, Zheng H, Lilly CM, O’Hanley PT, Raffin TA. The effects of aminophylline and pentoxyfylline on multiple organ damage after Escherichia coli sepsis. Am Rev Respir Dis. 1989; 140: 974-980
• 8 Welsh CH, Lien D, Worthen GS, Weil JV. Pentoxifylline decreases endotoxin induced pulmonary neutrophil sequestration and extravascular protein accumulation in the dog. Am Rev Respir Dis 1988; 138: 1106-1114
• 9 Chalkiadakis GE, Kostakis A, Karayannakos PE, Chalkiadakis ME, Sgouromali S, Giamarellou H, Skalkeas GD. Pentoxifylline in the treatment of experimental peritonitis in rats. Arch Surg 1985; 120: 1141-1144
• 10 Ishizaka A, Wu Z, Stephens KE, Harada H, Hogue RS, O’Hanley PT, Raffin TA. Attenuation of acute lung injury in septic guinea pigs by pentoxifylline. Am Rev Respir Dis 1988; 138: 376-382
• 11 Strieter RM, Remick DG, Ward PA, Spengler RN, Lynch JP, Larrick J, Kunkel SL. Cellular and molecular regulation of tumor necrosis factor alpha production by pentoxifylline. Biochem Biophys Res Commun 1988; 155: 1230-1236
• 12 Kneidinger R, Paul E, Redl H, Schlag G. Comparison of different xanthine derivates on monocyte and granulocyte function in vitro. Circ Shock 1991; 34: 141-142
• 13 Schade UF. Pentoxifylline increases survival in murine endotoxin shock and decreases formation of tumor necrosis factor. Circ Shock 1990; 31: 171-181
• 14 Zabel P, Wolter DT, Schönharting MM, Schade UF. Oxpentifylline in endotoxaemia. Lancet 1989; II: 1474-1477
• 15 DeProst D, Ollivier V, Hamkim J. Pentoxifylline inhibition of the generation of procoagulant activity by activated mononuclear phagocytes. Workshop Pentoxifylline and Analogues: Effects on Leukocyte Function, Le Mas d’Artigny. 1989; pp 10-11
• 16 Beretz A, Archipoff G, Camilla C, Brisson C, Klein-Soyer C, Freyssinet JM, Cazenave JP. Leukocyte-endothelium interactions and thrombosis: effects of pentoxifylline. Workshop Pentoxifylline and Analogues: Effects on Leukocyte Function, Le Mas d’Artigny 1989; p 14
• 17 Sullivan GW, Carper HT, Novick WJ, Mandell GL. Inhibition of the inflammatory action of interleukin 1 and tumor necrosis factor on neutrophil function by pentoxifylline. Infect Immun 1988; 56: 1722-1729
• 18 Waxman K. Physiologic effects of pentoxifylline in resuscitation of hemorrhagic shock. Workshop Pentoxifylline and Analogues: Effects on Leukocyte Function, Le Mas d’Artigny. 1989; pp 28-29
• 19 Boogaerts MA, Malbrain S, Meeus P, van Hove L, Verhoef GEG. In vitro modulation of normal and diseased human neutrophil function by pentoxifylline. Blut 1990; 61: 60-65
• 20 Tighe D, Moss R, Heath MF, Hynd J, Bennett ED. Pentoxifylline reduces pulmonary leucostasis and improves capillary patency in a rabbit peritonitis model. Circ Shock 1989; 28: 159-164
• 21 Gebert U, Okyayuz-Baklouti I, Thorwart W. Tertiary hydroxyalkylxanthines, procedure for their preparation, drugs containing them, and their use. Chem Abstr 1987; 106: 213648
• 22 Bahrami S, Leichtfried G, Redl H, Schlag G. A kinetic-chromogenic method to determine endotoxin on microplates. Eur Clin Lab 1991; Oct. 8
• 23 Friberger P, Knös M, Mellstam L. A quantitative endotoxin assay utilizing LAL and a chromogenic substrate. In: Endotoxin and their Detection with the Limulus Amebocyte Lysate Tests.. Watson S, Levin J, Novitsky TJ. (eds) Alan R Liss Inc, New York: 1982. pp 195-206
• 24 Von Asmuth EJU, Maessen JG, Van der Linden CJ, Buurman WA. Tumor necrosis factor-α (TNF) and interleukin 6 in a zymosan induced shock model. Scand Immunol 1990; 32: 313-319
• 25 Bahrami S, Paul E, Redl H, Schlag G. Therapeutic modalities to ameliorate endotoxin induced DIC in the rats. Prog Clin Biol Res 1989; 308: 977-982
• 26 Bahrami S, Redl H, Schlag G. Beeinflussung der durch Endotoxin verursachten DIC in der Ratte mittels Heparin, Antithrombin III, Antithrombin III-Heparin-Komplex oder Hirudin. Anaesthesist 1989; 38: S311
• 27 Moore JN, Cook JA, Morris DD, Halushka PV, Wise WC. Endotoxin-induced procoagulant activity, eicosanoid synthesis, and tumor necrosis factor production by rat peritoneal macrophages: Effect of endotoxin tolerance and glucan. Circ Shock 1990; 31: 281-295
• 28 Van der Poll T, Levi M, Büller H, van Deventer S, Boer J, Hack E. Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 1991; : 729-732
• 29 Van der Poll T, Büller H, ten Cate H, Wortel CH, Bauer KA, van Deventer SJH, Hack CE, Sauerwein HP, Rosenberg RD, ten Cate JW. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; : 1622-1627
• 30 Conway EM, Bach R, Rosenberg RD, Konigsberg WH. Tumor necrosis factor enhances expression of tissue factor mRNA in endothelial cells. Thromb Res 1989; 53: 231-241
• 31 Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone jr MA, Loskutoff DJ. Cytokine activation of vascular endothelium: effects on tissue-type plasminogen activator and type plasminogen activator inhibitor. J Biol Chem 1988; 263: 5797-5803
• 32 Van Hinsbergh VW, Kooistra T, van der Berg EA, Princen HM, Fiers W, Emels JJ. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human cells in vitro and in rats in vivo. Blood 1988; 72: 1467-1473
• 33 van Deventer SJH, Büller H, ten Cate JW, Aarden LA, Hack E, Sturk A. Experimental endotoxemia in humans: Analyses of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990; 76: 2520-2526
• 34 Lehmann V, Freudenberg MA, Galanos C. Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and Dgalactosamine-treated mice. J Exp Med 1987; 165: 657-663
• 35 Feuerstein G, Hallenbeck JM, Venatta B, Rabinovici R, Perera PY, Vogel SN. Effect of gram-negative endotoxin on levels of serum corticosterone, TNF-α, circulating blood cells, and the survival of rats. Circ Shock 1990; 30: 265-278
• 36 Waage A. Production and clearance of tumor necrosis factor in rats exposed to endotoxin and dexamethasone. Clin Immunol Immunopathol 1987; 45: 348-355
• 37 Enders S, Fülle HJ, Sinha B, Stoll D, Dinarello CA, Gerzer R, Weber PC. Cyclic nucleotides differentialy regulate the synthesis of tumor necrosis factor-α and interleukin-1β by human mononuclear cells. Immunology 1991; 72: 56-60
• 38 Bessler H, Gilgal R, Djaldetti M, Zahavi I. Effect of pentoxifylline on the phagocytic activity, cAMP levels, and superoxide anion production by monocytes and polymorphonuclear cells. J Leukocyte Biol 1986; 40: 747-754
• 39 Bahrami S, Redl H, Schlag G, Leichtfried G, Ceska M, Strieter RM. Comparison of the efficacy of different xanthine derivates to reduce endotoxin-induced mortality and/or cytokine production: in vivo and in vitro studies. Circ Shock 1991; 34: 140
• 40 Keppler DOR, Pausch J, Decker K. Selective uridine triphosphate deficiency induced by D-galactosamine in liver and reversed by pyrimidine nucleotide precursos. J Biol Chem 1974; 249: 211-216